Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland
Abstract
BACKGROUND
Metformin has anti-carcinogenic properties and is also known to inhibit the Sonic hedgehog pathway, but no population-based studies exist analyzing the potential protective effect for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
OBJECTIVES
To delineate the association between metformin use and invasive SCC, SCC in situ (SCCis) and BCC.
METHODS
A population-based case-control study design was employed using all 6,880 patients diagnosed in Iceland between 2003-2017 with first-time BCC, SCCis and invasive SCC, and 69,620 population controls. Multivariate odds ratios (ORs) were calculated using conditional logistic regression.
CONCLUSION
Metformin is associated with decreased risk of BCC development, even at low doses. Metformin might have potential as a chemoprotective agent for patients at high risk of BCC, although this will need confirmation in future studies.
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 6,880 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.